Final results of the capital increase
With the successful completion of the public offering to subscribe to the capital increase and the private placement of Scrips, both existing shareholders and new investors have subscribed to 100% of the offering, representing a total amount of EUR 247 million.
CEO Koen Dejonckheere & CFO Kristof Vande Capelle : “The successful completion of this capital increase is a crucial event in Gimv's 45-year history. It marks an important starting point as these funds strengthen our capital to support our accelerated growth strategy with the ambition to double our portfolio and to create additional value for our shareholders. We would like to thank our existing and new shareholders for their support and confidence. Now is the time to invest in our industry and economy. Gimv is more than ever ready to put these additional funds to work by doing what we do best: building leading companies.”
The 5,009,632 unexercised Preferential Rights (in the form of Scrips) were offered for sale on February 7, 2025 to Belgian and international investors by way of a private placement in the form of an accelerated bookbuilding (in other words, an accelerated private placement with composition of an order book) (the “Scrips Private Placement”).
Buyers of the Scrips have irrevocably committed themselves to exercise the Scrips and subscribe for 1,252,408 New Shares at the same subscription price and the same subscription ratio as the subscription through the exercise of Preferential Rights, i.e. 1 New Share (at EUR 34.50 per New Share) for 4 Preferential Rights.
With the successful completion of both the public offering and the Scrips Private Placement, existing shareholders and new investors now have subscribed for 100% of the New Shares offered for a total amount of EUR 246,794,370. The gross proceeds of the offer hence equal the targeted maximum of EUR 246,794,370 and the net proceeds of the offer are approximately EUR 242.1 million (after deduction of estimated costs and expenses).
Upon finalization of this capital increase and delivery of the New Shares, WorxInvest's shareholding in Gimv will increase from 29.9% to 32.3%, pursuant to the implementation of their subscription commitment.
The net proceeds from the sale of the Scrips, after deducting the costs, expenses and charges incurred by the Company in the context of the Scrips Private Placement (the “Net Proceeds of the Scrips”), amount to EUR 0.48 per unexercised (or qualified as such) Preferential Right. The Company expects that this amount shall be paid to these holders as from February 12, 2025.
Delivery of the New Shares is expected to take place on February 11, 2025. The New Shares will be tradable on the regulated market of Euronext Brussels, in principle as from the same date.
The trading of the shares of the Company on the regulated market of Euronext Brussels has been suspended, at the Company’s request, as from the opening of the markets on February 7, 2025 until shortly after the publication of this press release. With this phase being successfully completed, the Company requested to lift this suspension.
KBC Securities and Belfius Bank (in cooperation with Kepler Cheuvreux) act as Joint Global Coordinators and Joint Bookrunners for this transaction. Bank Degroof Petercam, BNP Paribas Fortis and ING Belgium act as Joint Bookrunners.
The prospectus is available on Gimv’s website: https://www.gimv.com/en/capital-increase.